Protein arginine methyltransferase-5 (PRMT5) plays a key role in lymphomagenesis, controlling the growth of transformed B cells. Furthermore, PRMT5 activity results in repression of multiple tumor suppressor genes including P53, RB, PTEN, E2F1, among others. However, the molecular mechanisms involved in PRMT5 oncogenic activity remain unclear.
The aims of our project are:
To investigate the potential therapeutic value of the first selective PRMT5 inhibitor, as a single agent or in combination with existing anticancer agents for lymphoma treatment.
To identify the mechanisms underlying PRMT5 overexpression in lymphoma.